Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
Data from the study showed that sacituzumab govitecan produced partial response in some patients suffering from metastatic esophageal and colorectal cancers, who were heavily pretreated.
Immunomedics developed sacituzumab govitecan by conjugating SN-38, the active metabolite of Pfizer’s (PFE) Camptosar (irinotecan), at a high drug-to-antibody ratio.
Results also showed the sacituzumab govitecan resulted in extended periods of stable disease in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases.
Moreover, repeated cycles of therapy with sacituzumab govitecan over many months were well-tolerated by patients and did not produce the typical side effects of irinotecan treatment other than neutropenia.
Immunomedics conducted additional preclinical testing, which indicated that it is suitable for combination therapy in these gastrointestinal cancers.
The company is also evaluating sacituzumab govitecan for the treatment of triple-negative breast cancer in patients who have failed prior therapies for metastatic disease.
Meanwhile, Immunomedics has built a pipeline of nine clinical-stage candidates and is working hard to develop them. Another candidate in Immunomedics’ ADC pipeline, labetuzumab govitecan, is in phase II development for the treatment of metastatic colorectal cancer. The company also has a worldwide collaboration with UCB S.A. (UCBJF) for candidate epratuzumab for the treatment of all non-cancer indications.
Immunomedics currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector include Biodel Inc. (BIOD) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment